Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Snags Global Rights to MEI’s Blood Cancer Drug in Expanded Deal
April 15, 2020
- Novartis’ Japan Sales Jump to 330.5 Billion Yen on Alcon Integration
April 15, 2020
- Lilly’s Japan Sales Grow 4.5% to 275 Billion Yen in 2019
April 15, 2020
- Ono Curbing Camostat Supplies after Drug Reported as Potential COVID-19 Hopeful
April 15, 2020
- Shionogi Aiming at Clinical Trials of COVID-19 Treatment Candidates in FY2020
April 15, 2020
- Peptide Institute Latest to Chip In with AnGes to Develop Novel Coronavirus Vaccine
April 15, 2020
- Gilead Launches PIII Remdesivir Trials for COVID-19 in Japan
April 15, 2020
- Sosei Kicks Off COVID-19 Drug Discovery Program
April 15, 2020
- Sanofi Files Sutimlimab for Cold Agglutinin Disease in Japan
April 14, 2020
- Opdivo Adds New Indication for Esophageal Cancer in South Korea
April 14, 2020
- Tokushukai Preparing Model Formulary for 72 Group Hospitals; PPIs, Flu Drugs Eyed
April 14, 2020
- Daiichi Sankyo, Nagoya Institute of Technology, Mitsubishi UFJ Capital Pair Up on Research for Vision Restoration Gene Therapy
April 14, 2020
- Daiichi Sankyo Staffer in Toyama Infected with Coronavirus
April 14, 2020
- Healios to Enroll COVID-19 Patients in PII Off-the-Shelf Cell Therapy Program for ARDS
April 14, 2020
- Shimadzu to Roll Out Coronavirus Detection Regent Kit on April 20
April 14, 2020
- After Valsartan, Towa Now Curbing Clindamycin Supplies as India Lockdown Continues
April 13, 2020
- Astellas’ AML Drug Xospata Accepted for Review in China
April 13, 2020
- Chugai Shifting Resources to Beef Up Drug Discovery Prowess: New Chief
April 13, 2020
- Manufacturer Restresses Caution against BCG Vaccine’s Off-Label Use for COVID-19
April 10, 2020
- Sanofi Launches Kevzara Trial for Severe COVID-19 in Japan
April 10, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…